     |
   |
|
|
Prior to joining Selecta Biosciences, Dr. Johnston was Vice President of Operations for Alkermes having responsibilities for process development, scale-up, and clinical manufacturing for pulmonary and sustained release injectable products as well as leadership of Alkermes 90,000 square foot manufacturing facility in Chelsea, MA. Dr. Johnston was also a project leader and member of Steering Committees for numerous products through various stages of development from Phase 1 through registration. Dr. Johnston was an original member of Advanced Inhalation Research (AIR®) Inc., a private company acquired by Alkermes in 1999. Prior to joining AIR, Lloyd was a professor in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He received his B.S. in Chemical Engineering from Queen's University in Canada, and his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Prior to joining Selecta, Dr. Lipford was Vice President of Basic Research at Coley Pharmaceutical Group until Pfizer’s acquisition in early 2008. His responsibilities were for the identification, exploration and development through first in man studies for cutting edge treatments in immune modulation. He began his relationship with Coley as a research consultant in 1997. In 2001 he joined Coley GmbH, in Langenfeld Germany, and in 2003 moved to Coley Inc., in Wellesley, MA where he assisted in coordinating the international R&D effort. Prior to this, Grayson was a leading academic member of the Institute for Medical Microbiology and Immunology at the Technical University of Munich for 10 years, authoring more than 70 peer-reviewed articles, book chapters and many patents in the fields of antigen presentation and immune activation and suppression. Dr. Lipford received his B.S. in Biology and Chemistry from Virginia Commonwealth University and received his Ph.D. in Immunology from Eastern Virginia Medical School.
Prior to joining Selecta Biosciences Mr. Abraham was Executive Director for Patents at Durect Corporation, a small-cap specialty pharmaceutical company. Previously he was Senior Patent Counsel for ALZA Corporation, a Johnson & Johnson company. Prior to working in-house at Durect and J&J, Mr. Abraham was employed by the law firms of Wilson Sonsini Goodrich and Rosati from, and Finnegan Henderson Farabow Garrett and Dunner. David also was a Patent Examiner at the United States Patent and Trademark Office. A specialist in both building field-defining patent portfolios for life sciences companies and negotiating complex partnering transactions, David has experience advising clients ranging from early stage startups to Big Pharma on intellectual property strategy and on transactional matters. David received his B.S. in Chemical Engineering from the University of Rochester and his J.D. from the George Washington School of Law.
Mr. Siewers has 30 years of experience in financial management, financial systems design and implementation, equity and debt financing, and mergers and acquisitions. Prior to joining Selecta, Mr. Siewers was an independent consultant for eight years providing strategic guidance and tactical implementation of accounting systems, management and regulatory reporting, internal controls, profitability and cost analysis to an array of clients ranging from startups to mid-level companies. Previously, David spent over 20 years in the financial services arena as CFO/SVP of Fleet Services Corporation and SVP of Putnam Investments. David graduated from Marietta College and received his CPA in 1978 while working at KPMG.